Parmax Pharma stake rises to 27.20% after share acquisition

Abhay Chinubhai Shah increased his shareholding in Parmax Pharma by acquiring 2,49,394 equity shares on June 18, 2026. This acquisition represents 2.76% of the total paid-up equity share capital of the company. The transaction was executed through an off-market mechanism at a price of ₹35.00 per share.

The disclosure was submitted in compliance with Regulation 18(6) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Abhay Chinubhai Shah is identified as PAC 8 within the group of acquirers. The shares were acquired from Pradeep Gosalia, Vandana Gosalia, and Nimit Gosalia.

Prior to this acquisition, the acquirers and PACs held 7,68,320 shares, accounting for 20.54% of the company's equity. Following the purchase, the combined shareholding has risen to 10,17,714 shares, which constitutes 27.20% of the total equity shares of the target company.

The consideration amount for the acquisition has been paid, although the shares are yet to be credited to the demat account of PAC 8. The acquirer group includes Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with several other PACs.

Shareholding Details

Description	Shares	Percentage
Total shareholding before acquisition	7,68,320	20.54%
Total shareholding after acquisition	10,17,714	27.20%

Acquisition Breakdown

Date	Mode	Seller	Purchase Price (₹)	Shares Acquired
18/06/2026	Off-market transaction	Pradeep Gosalia	35.00	2,49,194
18/06/2026	Off-market transaction	Vandana Gosalia	-	100
18/06/2026	Off-market transaction	Nimit Gosalia	-	100

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.00%	+10.39%	+108.36%	+141.41%	+108.36%	+36.34%

Dhiren Chandulal Shah and Sunil Chinubhai Shah have announced an open offer to acquire up to 26% of the expanded voting share capital of Parmax Pharma Limited at a price of ₹42.80 per share. The offer, aggregating to a total consideration of ₹10.04 crore, is being made in compliance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Fedex Securities Private Limited is acting as the manager to the offer.

The open offer is triggered by an underlying transaction involving a share purchase agreement and a proposed preferential issue. The acquirers, along with persons acting in concert (PACs), have entered into a Share Purchase Agreement dated June 08, 2026, to acquire 11,52,450 equity shares from existing promoters Alkesh Mahasukhlal Gopani, Vipul Mahasukhlal Gopani, and Pravina Mahasukh Gopani at ₹35.00 per share. Additionally, the board of directors of Parmax Pharma Limited approved a preferential issue of 31,37,586 equity shares and 21,45,145 warrants to the acquirers and PACs at ₹36.50 per share and warrant respectively.

Upon completion of the underlying transaction, the existing promoters will cease to hold any equity shares in the company and will be declassified from the promoter and promoter group category. The acquirers and PACs will acquire control over the target company and will be identified as the new promoters. The acquirers have stated they do not intend to delist the equity shares of Parmax Pharma Limited pursuant to this open offer.

The detailed public statement was published in newspapers on June 15, 2026. The offer is not conditional upon any minimum level of acceptance. The acquirers have confirmed they have adequate financial resources to meet the obligations under the SEBI (SAST) Regulations.

Offer Details

Parameter	Details
Offer Size	23,46,250 Equity Shares (26.00% of Expanded Voting Capital)
Offer Price	₹42.80 per Equity Share
Total Consideration	₹10,04,19,500 (assuming full acceptance)
Mode of Payment	Cash
Type of Offer	Mandatory open offer under Regulation 3(1) and 4

Transaction Summary

Transaction Type	Shares Acquired	Consideration
Share Purchase Agreement	11,52,450 Equity Shares	₹4,03,35,750
Preferential Issue - Equity Shares	31,37,586 Equity Shares	₹11,45,21,889
Preferential Issue - Warrants	21,45,145 Warrants	₹7,82,97,793
Total	64,35,181	₹23,31,55,432